BAY12-8039: 5 Days for Sinusitis vs Placebo
Sinusitis
About this trial
This is an interventional treatment trial for Sinusitis focused on measuring Respiratory Tract Infection, Bacterial Sinusitis
Eligibility Criteria
Inclusion Criteria:
Subjects must meet all the following criteria at the time of enrollment:
- Age >/= 18 years
Clinical diagnosis of acute bacterial sinusitis with signs and symptoms present for = 7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as follows:
- Radiographic Criteria: The presence of one or more of the following on a radiographic paranasal sinus film (Waters' view): - Evidence of air-fluid levels - Opacification
Clinical Criteria: The presence of two major symptoms, or the presence of at least one major and one minor symptom as defined in the list below:
- Major symptoms: - Purulent anterior or posterior nasal discharge - Unilateral facial pain or malar tenderness
- Minor symptoms: - Frontal headache - Fever (oral = 38.0°C/100.4°F, tympanic = 38.5°C/101.2°F, axillary = 37.5°C/99.5°F) - Culture material obtained by sinus puncture; the aspirated specimen sent for Gram stain, quantitative culture and susceptibility testing prior to initiation of antimicrobial therapy
Exclusion Criteria:
Subjects with one or more of the following criteria will not be eligible for this study:
- History of chronic sinusitis defined as greater than four weeks of continuous symptoms (subjects with recurrent acute sinusitis will be included)
- History of sinus surgery (antral sinus puncture is not considered as a surgery)
- Any symptoms that suggest the subject's current illness is allergic rhinitis (e.g. repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
- Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Moxifloxacin 400 mg
Placebo
Moxifloxacin 400mg once daily for 5 days
Matching placebo for 5 days